Treatment of neurodegenerative disease
A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Europäisches Patentamt - (2016) vom: 08. Nov. Zur Gesamtaufnahme - year:2016 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
BARBER ELIZABETH K [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2016-11-08, Last update posted on www.tib.eu: 2022-06-10, Last updated: 2023-02-09 |
---|
Patentnummer: |
US9486430 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA007669011 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA007669011 | ||
003 | DE-627 | ||
005 | 20230504123105.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210531s2016 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA007669011 | ||
035 | |a (EPA)US9486430 | ||
035 | |a (EPA)45975652 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a BARBER ELIZABETH K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Treatment of neurodegenerative disease |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2016-11-08, Last update posted on www.tib.eu: 2022-06-10, Last updated: 2023-02-09 | ||
520 | |a A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described. | ||
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2016) vom: 08. Nov. |
773 | 1 | 8 | |g year:2016 |g day:08 |g month:11 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/45975652/publication/US9486430A1?q=US9486430 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
912 | |a SSG-OLC-PHA | ||
936 | u | w | |j 2016 |b 08 |c 11 |
951 | |a AR | ||
952 | |j 2016 |b 08 |c 11 |